Search research articles
Contact Us
Filters
Showing results (151-160 of 269) with videos related to
Page
of 27
Sort By:
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
March 6, 2024
Alterations in the fecal microbiota in patients with advanced cystic fibrosis liver disease after 6 months of elexacaftor/tezacaftor/ivacaftor
Jennifer T Duong, Christopher E Pope, Hillary S Hayden, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
June 27, 2020
Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events
Carsten Schwarz, Sivagurunathan Sutharsan, Ralph Epaud, et al.
American Journal of Respiratory Cell and Molecular Biology
|
March 10, 2007
No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations
John P Clancy, Steven M Rowe, Zsuzsa Bebok, et al.
JCI Insight
|
January 12, 2018
Development of an airway mucus defect in the cystic fibrosis rat
Susan E Birket, Joy M Davis, Courtney M Fernandez, et al.
Redox Biology
|
May 10, 2021
LPS decreases CFTR open probability and mucociliary transport through generation of reactive oxygen species
Do Yeon Cho, Shaoyan Zhang, Ahmed Lazrak, et al.
Frontiers in Medicine
|
August 15, 2020
Fibroblast Growth Factor Receptor 4 Deficiency Mediates Airway Inflammation in the Adult Healthy Lung?
Molly Easter, Jaleesa Garth, Elex S Harris, et al.
The New England Journal of Medicine
|
November 4, 2017
Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis
Steven M Rowe, Cori Daines, Felix C Ringshausen, et al.
Plos One
|
August 8, 2013
Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation
Steven M Rowe, Bo Liu, Aubrey Hill, et al.
ERJ Open Research
|
June 21, 2019
Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two <i>F508del</i> alleles
Jennifer L Taylor-Cousar, Marcus A Mall, Bonnie W Ramsey, et al.
Biomedical Optics Express
|
October 25, 2019
Co-cultured microfluidic model of the airway optimized for microscopy and micro-optical coherence tomography imaging
Zhongyu Liu, Stephen Mackay, Dylan M Gordon, et al.
Page
of 27
Search research articles
Search
Showing results (151-160 of 269) with videos related to
Sort By:
Page
of 27
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
March 6, 2024
Alterations in the fecal microbiota in patients with advanced cystic fibrosis liver disease after 6 months of elexacaftor/tezacaftor/ivacaftor
Jennifer T Duong, Christopher E Pope, Hillary S Hayden, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
June 27, 2020
Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events
Carsten Schwarz, Sivagurunathan Sutharsan, Ralph Epaud, et al.
American Journal of Respiratory Cell and Molecular Biology
|
March 10, 2007
No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations
John P Clancy, Steven M Rowe, Zsuzsa Bebok, et al.
JCI Insight
|
January 12, 2018
Development of an airway mucus defect in the cystic fibrosis rat
Susan E Birket, Joy M Davis, Courtney M Fernandez, et al.
Redox Biology
|
May 10, 2021
LPS decreases CFTR open probability and mucociliary transport through generation of reactive oxygen species
Do Yeon Cho, Shaoyan Zhang, Ahmed Lazrak, et al.
Frontiers in Medicine
|
August 15, 2020
Fibroblast Growth Factor Receptor 4 Deficiency Mediates Airway Inflammation in the Adult Healthy Lung?
Molly Easter, Jaleesa Garth, Elex S Harris, et al.
The New England Journal of Medicine
|
November 4, 2017
Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis
Steven M Rowe, Cori Daines, Felix C Ringshausen, et al.
Plos One
|
August 8, 2013
Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation
Steven M Rowe, Bo Liu, Aubrey Hill, et al.
ERJ Open Research
|
June 21, 2019
Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two <i>F508del</i> alleles
Jennifer L Taylor-Cousar, Marcus A Mall, Bonnie W Ramsey, et al.
Biomedical Optics Express
|
October 25, 2019
Co-cultured microfluidic model of the airway optimized for microscopy and micro-optical coherence tomography imaging
Zhongyu Liu, Stephen Mackay, Dylan M Gordon, et al.
Page
of 27